Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sol-Gel Technologies ( (SLGL) ) has provided an update.
On March 23, 2026, Sol-Gel Technologies entered into an underwriting agreement for an oversubscribed underwritten offering of 459,112 ordinary shares at $72.00 per share, for expected gross proceeds of about $33.1 million, with closing anticipated around March 25, 2026 subject to customary conditions. The capital raise, backed by new and existing institutional investors and led by TD Cowen and LifeSci Capital, is intended to fund continued development and pre-commercialization of lead candidate SGT-610 and bolster working capital, underscoring investor confidence in Sol-Gel’s late-stage dermatology pipeline and its positioning in rare oncology-related skin disorders.
The offering attracted participation from prominent healthcare-focused funds, potentially broadening Sol-Gel’s institutional shareholder base and enhancing its visibility in the biopharmaceutical capital markets. By directing most of the proceeds to SGT-610’s Phase 3 program and related activities, the company is reinforcing its strategic focus on Gorlin syndrome and high-frequency basal cell carcinoma opportunities, while the use of an effective shelf registration streamlines access to future financing as it advances its portfolio.
The most recent analyst rating on (SLGL) stock is a Hold with a $73.00 price target. To see the full list of analyst forecasts on Sol-Gel Technologies stock, see the SLGL Stock Forecast page.
Spark’s Take on SLGL Stock
According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.
The score is driven primarily by improving financial trajectory (strong 2025 revenue rebound, positive operating/free cash flow, and very low debt) tempered by continued losses and equity erosion. Technicals are mixed/neutral, and valuation is pressured by a negative P/E and no dividend yield.
To see Spark’s full report on SLGL stock, click here.
More about Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a specialized dermatology company developing therapies for rare and serious skin diseases. Its lead investigational product, SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor for preventing new basal cell carcinoma lesions in Gorlin syndrome, alongside pipeline candidate SGT-210 and two FDA-approved products, TWYNEO and EPSOLAY.
Average Trading Volume: 27,465
Technical Sentiment Signal: Buy
Current Market Cap: $184.4M
See more data about SLGL stock on TipRanks’ Stock Analysis page.